This is achieved through the development of reliable
and non-invasive diagnostic tools that can be used
at any stage of the disease.

Biocross offers diagnostic solutions that can be used during the asymptomatic phase of the diseaseand enable early detection of individuals at higher risk of developing dementia.

Early Diagnosis

Biocross provides diagnostic solutions that can be used during the asymptomatic phase of the disease and enable early detection of individuals with increased risk of developing dementia.

Reliable

Biocross designed their products with a commitment to providing easy-to-use and cost-effective diagnostic tests of higher sensitivity and specificity than any currently available tests.

Non-invasive

All of our diagnostic tests are based on the analysis of blood samples, and are applicable in hospital settings, thus ensuring patient safety and comfort.

Biocross

Biocross is a biotechnology company that seeks to improve the life expectancy and quality of life of individuals with neurodegenerative diseases
through the design of innovative diagnostic systems.

Related Deseases

Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by memory loss, cognitive deterioration, and progressive functional dependence, ultimately leading to death.

Pipeline

Biocross is developing a series of blood tests for the diagnosis of Alzheimer’s disease with a view to providing neurologists with an integrated diagnostic solution applicable to any disease stage.

Products

e4Risk® is a non-genetic, cost-effective method for detecting the ApoE4 protein in blood plasma with high accuracy (100% sensitivity, 99% specificity). CE certified, FDA approval in progress.